The purpose of this study is to determine if CX157 is effective and safe in patients with treatment of treatment resistant depression over six weeks of treatment.
The primary objective of this study is to examine the efficacy of CX157 Modified Release Tablet, 125 mg administered twice per day (BID) as compared to placebo in subjects with Treatment Resistant Depression (TRD). Secondary objectives are to evaluate the safety and tolerability of CX157 Modified Release Tablet, 125 mg BID in TRD subjects and characterize steady-state pharmacokinetic profile and explore pharmacodynamic relationships.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
360
Placebo administered twice per day for six weeks.
One tablet administered twice per day (total daily dose of 250 mg) for six weeks.
Montgomery Asberg Depression Rating Scale (MADRS)
The MADRS will be administered by a trained rater at the study site and assess symptoms of depression.
Time frame: Over six weeks of study treatment
Severity of illness (CGI-S);
To measure severity of depression
Time frame: Over six weeks of treatment with study drug.
Global Improvement (CGI-I)
To measure overall improvment.
Time frame: Over six weeks of treatment
Hospital Anxiety Depression Rating Scale (HADS)
To measure symptoms of depression
Time frame: over six weeks of treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Synergy Escondido
Escondido, California, United States
Synergy Clinical Research Center
National City, California, United States
Excell Research
Oceanside, California, United States
Pacific Clinical Research
Orange, California, United States
Gulfcoast Clinical Research Center
Fort Myers, Florida, United States
Clinical Neuroscience Solutions, Inc.
Jacksonville, Florida, United States
The Segal Institute of Clinical Research
North Miami, Florida, United States
Clinical Neuroscience Solutions, Inc.
Orlando, Florida, United States
University of South Florida College of Medicine Psychiatry Center
Tampa, Florida, United States
Stedman Clinical Trials
Tampa, Florida, United States
...and 20 more locations